Preparation and characterization of zafirlukast- β-cyclodextrin complexes using solid dispersion techniques

International Journal of Pharmaceutical Sciences Review and Research

Volumn 4, Issue 1, 2010, Pages 88-93

  Radha Madhavi, B ^a   Kanaka Durga Devi, N ^a   Prameela Rani, A ^b  

^a KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b NIRMALA COLLEGE OF PHARMACY   (India)

Author keywords

Kneading method; Physical mixing; Solid dispersions; Solvent evaporation; Zafirlukast

Indexed keywords

BETA CYCLODEXTRIN; FUNCTIONAL GROUP; ZAFIRLUKAST;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DETERMINATION; DRUG MIXTURE; DRUG SOLUBILITY; EVAPORATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; SOLID DISPERSION; SOLVENT EVAPORATION;

EID: 79952032752     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Buccellati, C., Fumagalli, F., Viappiani, S., Folco G.: Leukotriene modifiers: novel therapeutics opportunities in asthma, Il Farmaco, 57, 235-242 (2002).
2. Dunn, C.J., Goa, K.L.: Zafirlukast: an update of its pharmacology and therapeutics efficacy in asthma, Drugs 61 (2) 285-315 (2001).
3. Balzano, G., Fuschillo, S., Gaudiosi, C.: Leukotriene receptor antagonists in the treatment of asthma: an update Allergy 57 (72), 16-19 (2002).
4. Dobetti L. Fast disintegrating tablets.US Patent 2003:6:596, 311.
5. Brown D. Orally disintegrating tablets-taste over speed. Drug Del tech 2003:3:58-61.
6. Seager H. Drug delivery products and the Zydis fastdissolving dosage form. J. Pharm Pharmacol 1998:50:375-82.
7. Chiou WL and Rigelman S. Pharmaceutical application of solid dispersion system. J. Pharm. Sci. 1971, 60:1281-1302.
8. Guyot M, Fawaz F, Bildet J. Physicochemical characterization and dissolution of norfloxacincyclodextrin inclusion compounds and PEG solid dispersions. Int. J. Pharm. 1995, 46:49-55.
9. Ukema K, Fujise A, Hirayama F, Otagiri M, Inaba K. Improvement of dissolution characteristics and chemical stability of prostaglandin El by cyclodextrin complexation. Chem. Pharm. Bull. 1984, 32:275-294.
10. Chow DD and Karana AH. Characterization, dissolution and bioavailability in rat s of ibuprofen-3-cyclodextrin complex system. Int. J. Pharm. 1986, 28:95-101.
11. Loftsson T, Guommundsdottir J, Sigurjonsdottir JF, Sigursson HH, Sigfusson SD, Masson M, Stefansson E. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int. J. Pharm. 2001, 212: 29-40.
12. Rajendrakumar K, Pralhad T, Madhusudan S. Comparative study on co-ground products of rofecoxib with beta-cyclodextrin and its sulfobutyl ether-7 derivative in solution and in the solid state. J. Incl. Phenom. Macro. Chem. 2004, 49:259-266.
13. Loftsson T and Brewster ME. Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85:1017-1025.
14. Rajewski A and Stella VJ. Pharmaceutical applications of cyclodextrins, 2. In vivo drug delivery, J. Pharm. Sci. 1996, 85:1142-1169.